next agonist
The three doors: the U.S. regulatory map for a melanocortin sun drug
The gray market makes Melanotan II look like the whole story of melanocortin tanning in America. It isn’t. It is one door of three — and by far the least interesting one. The technology this site keeps pointing at, a melanocortin agonist that builds photoprotective pigment without ultraviolet, is not hypothetical and not banned. One is already approved by the FDA. The real question was never whether this class of drug can be legal. It is which door a legitimate one comes through, and how far that door can open. This is that map — a primer for a technology that is arriving whether or not the gray market ever tidies itself up.
The door marked “approved” is already open
On October 8, 2019, the FDA approved a drug called SCENESSE. Its active ingredient, afamelanotide, is a selective agonist of the melanocortin-1 receptor — the same receptor at the center of how the tanning signal works, the same family Melanotan II hits. It is, in the plainest terms, a melanocortin agonist that works by driving the skin to make more eumelanin.
It was approved to prevent phototoxicity in adults with erythropoietic protoporphyria (EPP) — a rare inherited disorder in which sunlight triggers severe, burning skin pain. The label is precise: to increase pain-free light exposure in patients with a history of phototoxic reactions. It is delivered as a subcutaneous implant placed by a clinician every couple of months — a real medicine, administered like one, not a vial from a forum.
Sit with what that establishes. The FDA has already decided that a melanocortin agonist which protects skin by increasing pigment is approvable for a photoprotective use. The existential question — can this whole class of drug ever be a legitimate medicine for sun protection? — is answered. It already is, for the people who needed it most. Elsewhere this site covers afamelanotide as the middle-ground agonist you can’t have. Here it is something else: the proof that the front door opens.
Reading the map
Three doors lead toward an American with sun-sensitive skin. They are not equal.
Door one — FDA approval. A New Drug Application, usually smoothed by orphan- drug designation for a rare condition. It is slow, expensive, and merciless about evidence, and it is the only door that ends in a medicine you can trust. SCENESSE went through it. This is how the technology actually reaches people.
Door two — compounding. Licensed 503A and 503B pharmacies can compound certain drugs, and this is the ambiguous middle. For Melanotan II it is currently shut: the FDA places it in the restricted “Category 2” of bulk substances that may present significant safety risks, and it is not on the approved compounding list. Even the pharmacy route isn’t open to it today — though, tellingly, the FDA’s advisory committee is scheduled to review Melanotan II for that list around February 2027. The question of whether it partly legitimizes is, for the first time, formally on a calendar.
Door three — the gray market. The “research chemical, not for human consumption” trade, where Melanotan II has always actually flowed. It is not a pathway to legitimacy; it is a permanent side alley, and it is the subject of its own chapter. Nothing that travels through it ever becomes a trusted medicine, no matter how clinical the packaging looks.
Why approval clusters around disease, not sunshine
Here is the rule that governs the whole map, and the reason a melanocortin sun drug arrives the way it does. You do not get approved to help everyone tan safely. You get approved to treat a serious, specific, unmet medical need — and then you expand.
The logic is the beachhead. Claiming protection in healthy people forces you into the brutal arithmetic of the prevention-trial problem: proving a cancer or a burn didn’t happen, in enormous numbers, over years. Treating a disease — the phototoxic agony of EPP, the depigmentation of vitiligo — is a tractable trial with sick patients and a measurable endpoint. So approvals land on disease first, and the sunshine case follows behind.
That expansion is happening right now, with the very same molecule. Clinuvel’s CUV105 is a Phase III trial of afamelanotide in vitiligo, fully enrolled at more than 200 patients, with topline results expected in December 2026 and a pivotal follow-up trial planned to begin the same year — with regulatory engagement that explicitly includes North America. One melanocortin agonist, walking from its first approved indication toward its second. And the technology is diversifying beneath it: a separate oral MC1R agonist, MT-7117, is in trials for the protoporphyrias — melanocortin photoprotection beginning to escape the implant and reach toward a pill. This is not a stalled field. It is a beachhead widening.
The FDA polices the claim, not the molecule
One principle ties the whole American picture together — gray-market vials, supplement aisle, and approved medicine alike. What the FDA regulates most sharply is the claim.
Say “this protects you from the sun” without having proven it, and you draw a warning letter — it does not matter what form you took. In 2018 the agency hit four companies selling ingestible “sunscreen pills” as dietary supplements; the Commissioner’s line was blunt: there is no pill or capsule that can replace your sunscreen. The same enforcement logic sends warning letters to gray-market Melanotan distributors the instant they imply their vial is for tanning.
Which means a legitimate systemic sun drug is not defined by being an injection, an implant, or a pill. It is defined by having run the trials to earn the claim. SCENESSE is allowed to say “prevents phototoxicity in EPP” because it proved exactly that. Nobody else gets to say “protects your skin from the sun” until they do the same work. That is the bar — and for a claim about cancer and sunlight, it is the right one.
Where the door opens next
The rest is the site’s reading, offered as opinion rather than fact.
The arc will rhyme with the GLP-1 drugs. Those were approved for a disease (diabetes), expanded to a second (obesity), and from that narrow beginning went on to reset an entire culture’s relationship with a bodily norm — at scale, through the front door, as real medicine. A melanocortin agonist is on the first rungs of the same ladder: approved for EPP, in Phase III for vitiligo, an oral version coming up behind.
The honest near-term is not a mass-market tanning pill. It is disease-by-disease expansion into the populations who need photoprotection most and can anchor a trial: EPP and the other protoporphyrias, xeroderma pigmentosum, transplant recipients and others on immunosuppression whose skin-cancer risk is astronomical, solar urticaria, polymorphic light eruption, melanoma survivors. Each is a beachhead. Each widens what the word “approved” is allowed to cover.
Whether photoprotection ever broadens all the way to the general sun-sensitive public runs straight back into the prevention-trial wall — that is the real ceiling, and this site won’t pretend it isn’t there. But “hard” has never meant “never,” and the direction of travel is one-way. The door that Melanotan II could never use is the exact door the legitimate technology is already walking through, one indication at a time.
The gray market is a story about a molecule that got out. This is the more important story: a class of drug getting in, the right way. Keep your eye on the door marked approved.